tiprankstipranks
Sisram Medical’s DAXXIFY® Approved in China
Company Announcements

Sisram Medical’s DAXXIFY® Approved in China

Sisram Medical Ltd. (HK:1696) has released an update.

Don't Miss our Black Friday Offers:

Sisram Medical Ltd has announced the approval of its botulinum toxin type A product, DAXXIFY®, for cosmetic use in Mainland China, marking its first injectable product launch in the region. The Company obtained the sublicense rights in December 2022 for the commercialization of DAXXIFY® in Mainland China, Hong Kong, and Macau from Shanghai Fosun Pharmaceutical Industrial, with the original licensor being U.S.-based Revance Therapeutics, Inc. Sisram Medical expects DAXXIFY® to significantly bolster its product portfolio and strengthen its position in the global aesthetic market.

For further insights into HK:1696 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App